Analysis of the influencing factors of nausea and vomiting caused by moderate emetic chemotherapy drugs in advanced colorectal cancer
10.3969/j.issn.1673-9701.2025.24.015
- VernacularTitle:中度致吐化疗药物在晚期结直肠癌中引起恶心呕吐的影响因素分析
- Author:
Xiaolei LU
1
;
Zhen WANG
1
;
Bin SHEN
1
;
Wei DONG
1
Author Information
1. 嘉兴市第一医院药学部,浙江嘉兴 314001
- Publication Type:Journal Article
- Keywords:
Moderate vomiting;
Colorectal cancer;
Oxaliplatin;
Irinotecan;
Nausea and vomiting
- From:
China Modern Doctor
2025;63(24):73-79
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the factors for chemotherapy-induced nausea and vomiting(CINV)in patients with advanced colorectal cancer receiving moderately emetic chemotherapy regimens.Methods 296 patients with colorectal cancer treated with oxaliplatin/irinotecan combination therapy and standard antiemetic prophylaxis regimen at the First Hospital of Jiaxing from July 1,2022 to June 30,2024 were selected,including 164 patients in oxaliplatin combination therapy group and 132 patients in irinotecan combination therapy group.Evaluated the nausea and vomiting status of patients within 5 days after the start of chemotherapy.Analyzed demographic data,medical history data,follow-up data.Results The incidence of CINV in oxaliplatin combination therapy group was 61.59％,and that in irinotecan combination therapy group was 53.79％.The incidence of delayed CINV and severe acute CINV in oxaliplatin combination therapy group were significantly higher than those in irinotecan combination therapy group(P＜0.05).Multivariate analysis showed that the risk factors for acute CINV in the oxaliplatin-based combination regimen were smoking history and CINV history.The risk factors for delayed CINV were age,no history of drinking,history of pregnancy-induced vomiting,motion sickness history,CINV history,and first use of the regimen.For the irinotecan-based combination regimen,the risk factors for acute CINV were motion sickness history and CINV history.The risk factors for delayed CINV were CINV history and anxious emotions.Conclusion When useing standard anti-emetic prophylaxis that still have a high incidence of CINV by moderate emetic chemotherapy drugs in advanced colorectal cancer patients.Patients with high risk factors should actively take preventive measures to control CINV.
